吉西他滨联合培门冬酶、顺铂、地塞米松方案治疗晚期结外鼻型NK/T细胞淋巴瘤的临床效果分析

Clinical effect analysis of gemcitabine combined with pembellase,cisplatin and dexamethasone in the treatment of advanced extranodal nasal type NK/T cell lymphoma

目的:分析吉西他滨联合培门冬酶、顺铂、地塞米松方案治疗晚期结外鼻型NK/T细胞淋巴瘤的临床效果。方法:选取2017年4月至2018年6月于本院收治的50例结外鼻型NK/T细胞淋巴瘤患者为研究对象,将其随机划分为观察组与对照组。对照组采取吉西他滨联合培门冬酶治疗方案,观察组采取吉西他滨联合培门冬酶、顺铂、地塞米松方案,对比两组患者临床治疗效果。结果:观察组患者与对照组患者接受2~6周的化疗,在治疗过程中,观察组死亡2例,死亡率为8.0%。对照组患者死亡6例,死亡率为24.0%。两组患者临床疗效、治疗过程中不良反应率对比,观察组明显优于对照组。两组患者各项指标对比,组间数据差异具有统计学意义(P<0.05)。结论:吉西他滨联合培门冬酶、顺铂、地塞米松方案治疗晚期结外鼻型NK/T细胞淋巴瘤,应用疗效显著,可最大程度减少患者治疗过程中的不良反应与过敏发生率。

Objective:To analyze the clinical effects of gemcitabine combined with pembellase, cisplatin and dexamethasone in the treatment of advanced extranodal nasal type NK/T cell lymphoma. Methods: Fifty patients with extranodal nasal type NK/T-cell lymphoma admitted to our hospital from April 2008 to June 1818 were enrolled in the study. They were randomly divided into observation group and control group. The control group was treated with gemcitabine combined with Pemetrexase. The observation group was treated with gemcitabine combined with Pemetrex, Cisplatin and Dexamethasone to compare the clinical effects of the two groups. Results: Patients in the observation group and the control group received 2~6 weeks of chemotherapy. During the treatment, 2 patients died in the observation group, and the mortality rate was 8.0%. In the control group, 6 patients died and the mortality rate was 24.0%. The clinical efficacy and adverse reaction rate in the two groups of patients were significantly better than the control group. There were statistically significant differences in data between the two groups ( P < 0.05). Conclusion: Gemcitabine combined with Pembellase, Cisplatin and Dexamethasone in the treatment of advanced extranodal nasal type NK/T-cell lymphoma with significant therapeutic effect can minimize the incidence of adverse reactions and allergies during treatment.